Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108071300> ?p ?o ?g. }
- W3108071300 endingPage "100624" @default.
- W3108071300 startingPage "100624" @default.
- W3108071300 abstract "BackgroundThe dengue-infected patients with or without hemorrhagic manifestations, typically exhibit moderate to severe thrombocytopenia. A thrombopoietin receptor agonist – eltrombopag has been efficacious in correcting thrombocytopenia in patients with various pathological conditions including immune thrombocytopenia, chronic liver disease, and severe aplastic anemia. This study investigated the efficacy and safety of eltrombopag to correct dengue-mediated thrombocytopenia.MethodsIn this open-label, randomized controlled phase-II trial, patients with dengue fever (DF) and dengue hemorrhagic fever (DHF) having platelet (PLT) count lower than 100 × 109/L without comorbidity, pregnancy, and liver abnormalities were enrolled in Dhaka Medical College Hospital, Better Life Hospital and AMZ hospital, Dhaka, Bangladesh. Between October 10, 2019, and December 30, 2019, 123 DF and DHF patients were assessed for eligibility to be enrolled in the trial. Fourteen patients were excluded as they failed to fulfill the inclusion criteria (N = 6) or refused to participate in the trial (N = 8). Finally, 109 patients were randomly assigned to either Group 1, (N = 36), Group 2 (N = 37), or Control-group (N = 36) in a 1:1:1 ratio. Two doses of eltrombopag - 25 mg/day and 50 mg/day were administered to Group-1 and Group-2 patients, respectively whereas the control-group patients received standard dengue treatment without eltrombopag. The management of all enrolled patients was according to WHO guidelines. The randomization procedure was performed by using a computerized system (STATA Inc.). CBC and immature platelet fraction (IPF) were monitored from Day-0 to Day-7. Absolute immature platelet count (A-IPC) was calculated from PLT count and IPF for each patient. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured on Day-0 and Day-4 and an Ultrasonogram (USG) of the abdomen was performed on Day-4 and Day-7 for each patient. The efficacy of eltrombopag as the primary outcome of the trial was investigated by the proportion of patients with recovered platelet count receiving eltrombopag with corrected platelet count (platelet count above the lower normal limit: 150 × 109/L) on Day-7 of the enrollment as compared to the Control-group. As the secondary outcomes, the reduction of bleeding tendency in response to eltrombopag as well as the safety of eltrombopag in dengue patients were assessed. The safety was evaluated in case of adverse events, liver function enzymes AST/ALT levels and USG. This trial is registered with the international clinical trial registry, number SLCTR/2019/037.ResultsA total of 101 patients including 77 DF and 24 DHF patients completed the trial as eight patients left the trial without completing the follow-up. Patients of the different groups were compared with respect to mean age (26±8, 30±10 and 30±9 years for, Group-1,-2 and Control-group, respectively) (p-value= 0.23) and basal PLT count (Group-1: 58±24 × 109; Group-2: 52±29 × 109 and control-group: 55±30 × 109) (p-value= 0.63). The mean PLT counts for Group-1 (332 × 109/L ± 92) and Group-2 (371 × 109/L ± 111) were significantly higher than control-group (194 × 109/L ± 96) on Day-7 (adjusted p-value= 1.15 × 10−06 for Group-1 vs. Control-group, and adjusted p-value= 1.82 × 10−08 for Group-2 vs. Control-group).). On Day-7, 91% of Group-1 (N = 30) and Group-2 (N = 32) patients who received eltrombopag achieved primary endpoint of PLT count above than lower normal limit (150 × 109/L) (Group-1: 91%, OR: 8.33, 95% CI: 2.11 to 32.80, p-value: 0.0024 and Group-2: 91%, OR: 8.89, 95% CI: 2.26 to 34.89, p-value: 0.0017) compared to 55% (N = 18) of control-group patients who did not receive eltrombopag. The bleeding manifestations for thirteen out of fourteen grade-II DHF patients were subsided within Day-7 who received eltrombopag, whereas four out of ten grade-II DHF patients with PLT counts lower than the lower normal limit in the control group showed intermittent bleeding symptoms throughout the trial period. Mean A-IPC but not IPF was significantly higher for eltrombopag-treated groups in comparison to the Control-group. The frequency of the most common adverse events (vomiting and diarrheal tendencies) was similar in the treated-and control-groups (N = 5, 15%, and N = 3, 9% for Group-1 and -2, respectively vs. N = 4, 12% in the Control-group). Ten (30%) patients of Group-1 and, fourteen (40%) patients of Group-2 showed increased AST (U/L) as opposed to nine patients (27%) in the Control-group. Increased ALT levels were observed for three (9%), nine (26%), and seven (21%) patients belonging to the Group-1, -2, and Control-group, respectively. PLT counts higher than the upper normal limit (450 × 109/L) on Day-7 were observed for seven patients who were administered the higher dose (50 mg/day) in contrast to the three patients receiving the lower dose (25 mg/day). USG reports did not show thrombosis events in any of the patients.InterpretationThe trial revealed that the administration of eltrombopag in a short regimen for three days was efficacious to restore the PLT count in DF and DHF patients. The higher number of A-IPCs in eltrombopag treated patients underscored the possible mode of action of eltrombopag through stimulating megakaryopoiesis in dengue patients. The trial hints toward the positive effect of eltrombopag in the cessation of bleeding manifestation. Administration of the lower dose (25 mg/day) of eltrombopag was shown to be safer and equally efficacious to the higher dose (50 mg/day) in treating dengue-infected patients." @default.
- W3108071300 created "2020-12-07" @default.
- W3108071300 creator A5003254343 @default.
- W3108071300 creator A5008293391 @default.
- W3108071300 creator A5016144198 @default.
- W3108071300 creator A5018713516 @default.
- W3108071300 creator A5047940271 @default.
- W3108071300 creator A5054753320 @default.
- W3108071300 creator A5078518924 @default.
- W3108071300 creator A5082819197 @default.
- W3108071300 creator A5084145960 @default.
- W3108071300 creator A5086935915 @default.
- W3108071300 creator A5089167747 @default.
- W3108071300 date "2020-12-01" @default.
- W3108071300 modified "2023-10-15" @default.
- W3108071300 title "Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial" @default.
- W3108071300 cites W1973020193 @default.
- W3108071300 cites W1974541132 @default.
- W3108071300 cites W1980002878 @default.
- W3108071300 cites W2009094928 @default.
- W3108071300 cites W2009296003 @default.
- W3108071300 cites W2013946336 @default.
- W3108071300 cites W2025122282 @default.
- W3108071300 cites W2039002753 @default.
- W3108071300 cites W2042479028 @default.
- W3108071300 cites W2056147490 @default.
- W3108071300 cites W2056173679 @default.
- W3108071300 cites W2065460230 @default.
- W3108071300 cites W2067193640 @default.
- W3108071300 cites W2081223518 @default.
- W3108071300 cites W2082696395 @default.
- W3108071300 cites W2084853186 @default.
- W3108071300 cites W2088608752 @default.
- W3108071300 cites W2090229245 @default.
- W3108071300 cites W2103398208 @default.
- W3108071300 cites W2103818290 @default.
- W3108071300 cites W2104115143 @default.
- W3108071300 cites W2108532099 @default.
- W3108071300 cites W2127175732 @default.
- W3108071300 cites W2139478711 @default.
- W3108071300 cites W2145439228 @default.
- W3108071300 cites W2157675733 @default.
- W3108071300 cites W2161370760 @default.
- W3108071300 cites W2174217532 @default.
- W3108071300 cites W2352796693 @default.
- W3108071300 cites W2410341838 @default.
- W3108071300 cites W2583681475 @default.
- W3108071300 cites W2586334726 @default.
- W3108071300 cites W2593163687 @default.
- W3108071300 cites W2594067265 @default.
- W3108071300 cites W2605781925 @default.
- W3108071300 cites W2606996549 @default.
- W3108071300 cites W2608926487 @default.
- W3108071300 cites W2736836364 @default.
- W3108071300 cites W2809088984 @default.
- W3108071300 cites W2944617176 @default.
- W3108071300 cites W2989959092 @default.
- W3108071300 cites W4211002680 @default.
- W3108071300 cites W4211263076 @default.
- W3108071300 cites W92486268 @default.
- W3108071300 doi "https://doi.org/10.1016/j.eclinm.2020.100624" @default.
- W3108071300 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7691733" @default.
- W3108071300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33294822" @default.
- W3108071300 hasPublicationYear "2020" @default.
- W3108071300 type Work @default.
- W3108071300 sameAs 3108071300 @default.
- W3108071300 citedByCount "6" @default.
- W3108071300 countsByYear W31080713002021 @default.
- W3108071300 countsByYear W31080713002022 @default.
- W3108071300 countsByYear W31080713002023 @default.
- W3108071300 crossrefType "journal-article" @default.
- W3108071300 hasAuthorship W3108071300A5003254343 @default.
- W3108071300 hasAuthorship W3108071300A5008293391 @default.
- W3108071300 hasAuthorship W3108071300A5016144198 @default.
- W3108071300 hasAuthorship W3108071300A5018713516 @default.
- W3108071300 hasAuthorship W3108071300A5047940271 @default.
- W3108071300 hasAuthorship W3108071300A5054753320 @default.
- W3108071300 hasAuthorship W3108071300A5078518924 @default.
- W3108071300 hasAuthorship W3108071300A5082819197 @default.
- W3108071300 hasAuthorship W3108071300A5084145960 @default.
- W3108071300 hasAuthorship W3108071300A5086935915 @default.
- W3108071300 hasAuthorship W3108071300A5089167747 @default.
- W3108071300 hasBestOaLocation W31080713001 @default.
- W3108071300 hasConcept C126322002 @default.
- W3108071300 hasConcept C141071460 @default.
- W3108071300 hasConcept C168563851 @default.
- W3108071300 hasConcept C187212893 @default.
- W3108071300 hasConcept C203014093 @default.
- W3108071300 hasConcept C204243189 @default.
- W3108071300 hasConcept C2778715236 @default.
- W3108071300 hasConcept C2780588981 @default.
- W3108071300 hasConcept C2993327898 @default.
- W3108071300 hasConcept C533803919 @default.
- W3108071300 hasConcept C71924100 @default.
- W3108071300 hasConcept C89560881 @default.
- W3108071300 hasConcept C90924648 @default.
- W3108071300 hasConceptScore W3108071300C126322002 @default.
- W3108071300 hasConceptScore W3108071300C141071460 @default.